NovaBridge Biosciences
NovaBridge Biosciences is a biotechnology platform company that identifies and develops therapeutic assets for global markets through strategic partnerships and specialized subsidiaries. Its clinical pipeline includes givastomig, a bispecific antibody targeting CLDN18.2 and 4-1BB for gastric and other cancers; uliledlimab, whose internal development is paused; and ragistomig, which is managed by collaboration partner ABL Bio. Through its subsidiary Visara, NovaBridge develops VIS-101, a biologic targeting VEGF-A and ANG-2 for wet age-related macular degeneration and diabetic macular edema. It also holds rights to bispecific and multi-specific applications based on the CLDN18.2 parental antibody used in givastomig, subject to a collaboration agreement with ABL Bio. NovaBridge advances assets through development partnerships and licenses, and its agreements include payments tied to rights, development, regulatory milestones and royalties. It is headquartered in Rockville, Maryland.
No SEC Form 4 filings for $NBP in the last 30 days.
See all $NBP insider activity →I-Mab (NASDAQ: NBP) selected the 8 mg/kg dose of givastomig for further development after Phase 1b trial data showed promising results in gastric cancer. The company reported manageable safety profile and FDA alignment on key design elements for the registrational program. The 8 mg/kg dose showed a balance between efficacy and toxicity, with notable durability in frontline treatment.
NovaBridge Biosciences (NASDAQ: NBP) appointed Chuck Silberstein, M.D., M.B.A., as CFO, effective November 2. Silberstein has over 25 years of experience in biotechnology and finance, previously serving as CFO at GentiBio and Applied Therapeutics. The company focuses on developing therapeutic assets, including givastomig for gastrointestinal malignancies.
NovaBridge Biosciences (NASDAQ: NBP) presented Phase 1b data for givastomig in gastric cancer treatment at ESMO 2026. The 8 mg/kg dose showed 79% objective response rate and 16.9 months median progression-free survival. The company plans registrational development and has FDA alignment. Givastomig has Orphan and Fast Track designations.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning NBP (NovaBridge Biosciences). Coverage has skewed bullish: 2 bullish, 2 neutral, and 0 bearish.
Recent NBP coverage spans technology, financial news and earnings.
Positive early-phase data may boost investor confidence and drive short-term price appreciation.
The CFO appointment could enhance capital market execution and financing strategy.
Strong efficacy signals may drive share price higher.
Acquisition expands pipeline in ocular oncology.
Positive Phase 1b data may boost investor sentiment for NBP.
AlphAI scores every news story that mentions NBP with an AI model for sentiment and relevance, and aggregates insider trades from NovaBridge Biosciences's SEC EDGAR Form 4 filings. Figures refresh continuously.
I-Mab (NASDAQ: NBP) selected the 8 mg/kg dose of givastomig for further development after Phase 1b trial data showed promising results in gastric cancer. The company reported manageable safety profile and FDA alignment on key design elements for the registrational program. The 8 mg/kg dose showed a balance between efficacy and toxicity, with notable durability in frontline treatment.
2 min readNovaBridge Biosciences (NASDAQ: NBP) appointed Chuck Silberstein, M.D., M.B.A., as CFO, effective November 2. Silberstein has over 25 years of experience in biotechnology and finance, previously serving as CFO at GentiBio and Applied Therapeutics. The company focuses on developing therapeutic assets, including givastomig for gastrointestinal malignancies.
1 min readNovaBridge Biosciences (NASDAQ: NBP) presented Phase 1b data for givastomig in gastric cancer treatment at ESMO 2026. The 8 mg/kg dose showed 79% objective response rate and 16.9 months median progression-free survival. The company plans registrational development and has FDA alignment. Givastomig has Orphan and Fast Track designations.
2 min readAstraZeneca (AZN) received FDA approval for Ultomiris in IgA nephropathy, with a 43.4% reduction in proteinuria. Merck (MRK) got EU approval for KEYTRUDA plus Padcev in bladder cancer, showing a 35% reduction in death risk. Alvotech (ALVO) approved a new manufacturing process for SIMLANDI. Cytokinetics (CYTK) won Health Canada approval for MYQORZO in obstructive HCM. Viatris (VTRS) approved RYZUMVI for presbyopia. Enlivex (ENLV) and EyePoint (EYPT) announced significant workforce reductions.
3 min readHiteck licensed its experimental eye drop, HT006.2.2, to Visara for neurotrophic keratitis treatment outside Greater China. In a Phase 1b study, 50% of high-dose subjects achieved complete corneal healing after 8 weeks. Visara, a subsidiary of NovaBridge Biosciences (NBP), will develop and commercialize the therapy.
2 min readNovaBridge Biosciences (NBP) will present updated Phase 1b trial data for givastomig at ESMO Congress 2026. The study evaluates givastomig in combination with nivolumab and chemotherapy for advanced gastroesophageal adenocarcinoma. The FDA has granted Fast Track Designation to givastomig for this indication.
3 min readNovaBridge Biosciences (NBP) reported a wider H1 2026 net loss of $37.9M ($0.14 per share) vs. $8.7M ($0.05) a year ago. R&D and admin expenses rose, with cash reserves at $215.9M. The company advanced givastomig (Phase 3 interim data expected 2028) and VIS-101 (Phase 2b study planned H2 2026). NBP stock closed at $1.98, up 4.76%.
3 min readNovaBridge Biosciences (NBP) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution • Executing NovaBridge’s strategy to identify differentiated science, develop it efficiently and create long-term value for patients and shareholders • Appoi
2 min readPakistan’s Finance Division notified that Rehmat Ali Hasnie’s term as President and CEO of National Bank of Pakistan (NBP) is extended by 14 days, effective Aug. 7, 2026, until a successor takes office or the two weeks end, under the Banks (Nationalization) Act, 1974. NBP said the extension was communicated to Pakistan Stock Exchange TRE certificate holders.
3 min readPakistan’s central bank, the State Bank of Pakistan (SBP), appointed 10 Primary Dealers and two Special Purpose Primary Dealers for fiscal year 2026-27. UBL, NBP and Bank Alfalah were top performers in FY2025-26, per an SBP notification. PDs support auctions, distribution and secondary trading of government securities as the government relies on domestic borrowing.
3 min read
